Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778996 · ClinicalTrials.gov registry record · Phase 2
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma
A Phase 2 study of Sarcoma and Sarcoma, Ewing, sponsored by Sarcoma Oncology Research Center.
- Active
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03778996 is a Phase 2 study of Sarcoma and Sarcoma, Ewing that is active but no longer recruiting, run by Sarcoma Oncology Research Center. The registered enrollment target is 31 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03778996, a Phase 2 study of Sarcoma and Sarcoma, Ewing, is active but no longer recruiting, sponsored by Sarcoma Oncology Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment * Clinically advanced sarcoma patients in the salvage treatment setting Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.
Conditions Studied
Interventions
- DRUG Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
Study Locations (1)
California
- Sarcoma Oncology Research Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-01-03 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03778996
The ClinicalTrials.gov registry entry for NCT03778996 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) is the first listed.
NCT03778996 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03778996 about?
NCT03778996 is a clinical study titled "SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma". The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment * Clinically advanced sarcoma patients in the salvage treatment ...
What is the current status of trial NCT03778996?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-01-03. Estimated completion is 2028-03-31.
What conditions does trial NCT03778996 study?
This clinical trial studies the following conditions: Sarcoma, Sarcoma, Ewing.
What interventions are being tested in trial NCT03778996?
The interventions under investigation include: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) (DRUG).
Who is sponsoring clinical trial NCT03778996?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03778996 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.